- Home
- RLAY vs EWTX Comparison
RLAY vs EWTX Comparison
Compare RLAY & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | EWTX |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLAY | EWTX |
|---|---|---|
| Price | $20.01 | $45.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $19.50 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 4.2M | 1.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $3.03 | $12.31 |
| 52 Week High | $20.79 | $48.40 |
Technical Indicators
Market Signals| Indicator | RLAY | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 64.21 |
| Support Level | $12.10 | $29.03 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.31 | 2.71 |
| MACD | 0.17 | 0.66 |
| Stochastic Oscillator | 85.38 | 74.16 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.